Ptc Therapeutics (PTCT) Common Equity (2016 - 2025)
Historic Common Equity for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to -$155.8 million.
- Ptc Therapeutics' Common Equity rose 8522.71% to -$155.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$155.8 million, marking a year-over-year increase of 8522.71%. This contributed to the annual value of -$1.1 billion for FY2024, which is 3414.75% down from last year.
- According to the latest figures from Q3 2025, Ptc Therapeutics' Common Equity is -$155.8 million, which was up 8522.71% from -$206.5 million recorded in Q2 2025.
- In the past 5 years, Ptc Therapeutics' Common Equity ranged from a high of $292.6 million in Q1 2021 and a low of -$1.1 billion during Q4 2024
- In the last 5 years, Ptc Therapeutics' Common Equity had a median value of -$226.9 million in 2022 and averaged -$387.0 million.
- As far as peak fluctuations go, Ptc Therapeutics' Common Equity tumbled by 2423671.77% in 2022, and later soared by 8522.71% in 2025.
- Quarter analysis of 5 years shows Ptc Therapeutics' Common Equity stood at $1.4 million in 2021, then crashed by 24236.72% to -$347.1 million in 2022, then plummeted by 135.84% to -$818.6 million in 2023, then crashed by 34.15% to -$1.1 billion in 2024, then soared by 85.82% to -$155.8 million in 2025.
- Its Common Equity stands at -$155.8 million for Q3 2025, versus -$206.5 million for Q2 2025 and -$185.8 million for Q1 2025.